CHOOSING SMART EMBRYOS ISN'T IMMORAL.

AuthorBailey, Ronald
PositionSCIENCE

LET'S SAY YOU'RE a fertility doctor advising would-be parents who have exactly two viable embryos ready for implantation. The parents want to implant only one embryo. This is not an uncommon scenario; more than 71,000 babies were born in the U.S. via assisted reproduction in 2016.

For several decades now, folks using in vitro fertilization (IVF) have also tested for the single genes associated with certain heritable genetic diseases (such as cystic fibrosis, Huntington's disease, or hemophilia) and chromosomal abnormalities (such as those that cause Down syndrome). Nearly three-quarters of Americans approve of this pre-implantation genetic diagnosis (PGD) testing for diseases that are fatal early in life, according to a 2015 survey in the Journal of Assisted Reproduction and Genetics, and two-thirds support it for conditions that cause lifelong disability.

But let's say that in the case of these two embryos, you have more information. Perhaps test results indicate that both embryos are physically healthy but also suggest that one of them is five times less likely to complete college than the other. Or perhaps the only discernible difference between the two embryos is a higher likelihood of coronary disease, which manifests late in life and is typically manageable with medication.

Stephen Hsu, vice president for research at the New Jersey genetic testing startup Genomic Prediction, raises hypothetical like these and asks, "Do you tell the parents this information?"

The right answer to Hsu's question is yes, if the parents want to know.

MOST COMMON ILLNESSES that afflict people are not the result of single gene defects but the aggregate of hundreds or thousands of different genes. By comparing whole genome sequences from large numbers of people to the diseases and traits reported in their medical records, however, researchers are now able to determine "polygenic" risk scores for such illnesses as diabetes, atrial fibrillation, inflammatory bowel disease, and breast cancer.

Based on the results of rapidly multiplying studies on these scores, genetic testing companies have begun offering to test IVF embryos for a wide variety of diseases. According to Genomic Prediction, its Expanded Pre-Implantation Genomic Testing "allows the routine, inexpensive evaluation of hundreds of thousands of genetic variants," enabling the company to generate polygenic risk...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT